BSE has levied a fine on the Company due to non-submission of financial results for the Quarter ended 30th September, 2025, within the period as prescribed under Regulation 33 of SEBI LODR
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BSE has imposed a fine of Rs. 1,47,500 (Rs. 1,25,000 basic + Rs. 22,500 GST) on Indrayani Biotech Ltd for late submission of its unaudited financial results (standalone and consolidated) for the quarter ended 30th September 2025, under Regulation 33 of SEBI LODR Regulations. The fine works out to Rs. 5,000 per day for the period of delay. The company says the delay was caused by additional information and clarifications sought by its Audit Committee, and it had already intimated BSE about the postponement on 14th November and 5th December 2025. The financial results were eventually submitted on 11th December 2025, and the company will pay the fine within the prescribed 15-day timeline.
The financial impact is minor — the fine is a small amount relative to the company's operations and has already been provided for. However, BSE has warned that a second consecutive year of Regulation 33 non-compliance could result in the stock being moved to the Z group and suspension of trading, which is a more serious risk for shareholders to monitor going forward.